financetom
Business
financetom
/
Business
/
Meta partners with Midjourney to license AI tech for future products
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Meta partners with Midjourney to license AI tech for future products
Aug 22, 2025 4:16 PM

(Reuters) -Meta has signed a deal with generative AI lab Midjourney to license the startup's "aesthetic technology" for the social media company's future models and products.

The technical collaboration will link the companies' research teams, Alexandr Wang, the Facebook parent's chief AI officer, said on Friday.

The move signals Meta's push to differentiate its products on visual quality, as it looks to revitalize its artificial intelligence efforts amid heated competition with rivals, including ChatGPT-maker OpenAI and Google.

Midjourney, which generates images from text prompts, licenses its tools to users through a subscription model.

"We are incredibly impressed by Midjourney," Wang said in a post on X, adding that to deliver best products, Meta is combining top talent, a strong compute roadmap and partnerships with leading industry players.

Meta and Midjourney did not immediately respond to Reuters' requests for comment.

The startup's image-generation prowess could help Meta accelerate creative features for users and marketers, potentially lowering content production costs and boosting engagement.

The deal comes at a time when Meta has reorganized its AI efforts under Superintelligence Labs, a high-stakes push that followed senior staff departures and lukewarm reception for its latest open-source Llama 4 model.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-Ipsen To Acquire Imcheck Therapeutics
BRIEF-Ipsen To Acquire Imcheck Therapeutics
Oct 21, 2025
Oct 22 (Reuters) - Ipsen SA: * IPSEN TO ACQUIRE IMCHECK THERAPEUTICS, EXPANDING ITS LEADERSHIP IN ONCOLOGY, STRENGTHENING ITS PIPELINE * TO BUY IMCHECK THERAPEUTICS FOR 350 MILLION EUROS * TOTAL POTENTIAL CONSIDERATION UP TO 1 BILLION EUROS * TRANSACTION IS EXPECTED TO CLOSE BY END OF Q1 2026 Source text: Further company coverage: (Gdansk Newsroom) ...
Russia's Orenburg plant restarts taking gas from Kazakhstan field, energy minister says
Russia's Orenburg plant restarts taking gas from Kazakhstan field, energy minister says
Oct 21, 2025
Oct 22 (Reuters) - Russia's Orenburg gas plant has restarted receiving natural gas from Kazakhstan's Karachaganak field, Kazakhstan's energy minister said on Wednesday. ...
Trump administration plans new probe into global drug pricing, FT reports
Trump administration plans new probe into global drug pricing, FT reports
Oct 21, 2025
(Reuters) -President Donald Trump's administration is preparing a new probe into drug pricing practices among U.S. trading partners, a move that would lay the ground for fresh tariffs, the Financial Times reported on Wednesday, citing sources familiar with the matter.  Reuters could not immediately verify the report.  The imminent investigation would consider whether U.S. trading partners are underpaying for drugs,...
Advent International considering $2 billion sale of Parfums de Marly business, FT reports
Advent International considering $2 billion sale of Parfums de Marly business, FT reports
Oct 21, 2025
Oct 22 (Reuters) - Private equity firm Advent International is in early discussions to potentially sell its Parfums de Marly business as soon as next year at a likely valuation of more than $2 billion, the Financial Times reported on Wednesday. The Boston-based investor is yet to hire bankers or make a final call on a potential divestment, FT said,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved